Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
about
Activation of p53 by chemotherapeutic agents enhances reovirus oncolysisCompound A398, a novel podophyllotoxin analogue: cytotoxicity and induction of apoptosis in human leukemia cellsA better experimental method to detect the sensitivity of cancer cells to anticancer drugs after adenovirus-mediated introduction of two kinds of p53 in vivoAurora kinases in head and neck cancerDisrupting the networks of cancerAdaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell deathA 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations.Tumor control versus adverse events with targeted anticancer therapies.Overview of fundamental study of pazopanib in cancer.Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.Anti-cancer applications of titanocene-functionalised nanostructured systems: an insight into cell death mechanisms.Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
P2860
Q28485141-418D77CD-F421-4CD7-BD9A-9424816D9F24Q28542976-F129B00E-400A-415E-B14A-95800D8D84F9Q28546961-ED4D8F67-ED22-487D-AA6D-4EEF132ED98EQ28654389-9B5643DA-E542-4B5D-B224-BCE94DFB9B3FQ28656016-43E304AD-4AED-491C-AAC8-FAE5C9981475Q34458459-C175BB77-B1BA-40A1-B29C-F334CE1D9854Q35476091-0D071B7D-5558-469A-B84C-DF7358802B55Q36976738-B42DAFA2-FD49-469C-8805-1D25EA9E4A3FQ37832439-E79DDAD6-21D2-407A-9725-1A360D59ADFCQ37969899-CC0C4BA1-D5F7-48A4-84D7-810919CA4698Q38696525-F0431721-72A1-4E7A-84C9-E5FD2B529DCFQ38892678-30E31E95-401A-4A6C-B682-EB2DDC031359Q39006059-5FCE76F0-2E61-4BAF-8907-D002423F2859Q39396223-8CB2E5E4-D50D-445C-8B6F-C2BE7A127B08Q50238528-ECE68D14-31B2-4CF7-B6B4-D647392F04C7Q53698804-F852BBCF-A99B-42AC-A39C-79F65722A374
P2860
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@en
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@nl
type
label
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@en
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@nl
prefLabel
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@en
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@nl
P2093
P2860
P356
P1476
Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
@en
P2093
Elizabeth A Hopper-Borge
Erica A Golemis
Igor Astsaturov
Ilya G Serebriiskii
Tetyana V Bagnyukova
P2860
P304
P356
10.4161/CBT.10.9.13738
P577
2010-11-01T00:00:00Z